glp 1 generic First GLP-1 Injection OK'd for Weight Loss FDA approves 1st generic GLP-1

Asia-Pacific is the fastest-growing regional GLP-1 drug market at 22.6% CAGR , driven by rapidly rising obesity prevalence China now reports 18.6% adult obesity prevalence up from 7.1% in 2000 combined with expanding private health insurance and regulatory approvals

Type 2 diabetes Treatment summaries, BNF NICE

In any other context, the risk of bias was considered to be some concerns (scored as 2)

FDA labeling notes that delayed gastric emptying may affect absorption of oral medications and that these agents are not recommended for patients with severe gastroparesis

conducted a retrospective analysis of 120 IBD patients treated with GLP-1 receptor agonists and found a significant reduction in CRP levels over one year (12.92 vs